The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 04, 2017

Filed:

Mar. 16, 2016
Applicant:

Bridge Pharma, Inc., Sarasota, FL (US);

Inventors:

A.K. Gunnar Aberg, Sarasota, FL (US);

Vincent B. Ciofalo, Branford, CT (US);

Keith Johnson, Durham, NC (US);

Assignee:

BRIDGE PHARMA, INC., Sarasota, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/445 (2006.01); A61K 31/4535 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4535 (2013.01); A61K 9/0043 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 45/06 (2013.01);
Abstract

Disclosed herein are methods of treating a mammal in need of a reduction in intraocular pressure by administering an intraocular formulation including a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the mammal in need thereof, wherein the intraocular formulation includes about 0.02 wt % to about 1.0 wt % norketotifen or a salt or an isomer thereof, calculated as the norketotifen free base. In certain aspects, the intraocular formulation is free from any added preservative and the intraocular formulation is self-preserving. Also included herein is a method of treating a human in need of a reduction in intraocular pressure by administering an intranasal formulation that includes a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the human in need thereof. Also, the beneficial effects of known drugs for high IOP are improved by co-administration with norketotifen.


Find Patent Forward Citations

Loading…